FRE PMTA Status 2026: Where Every SKU Stands with FDA

TL;DR

As of June 26, 2026, FRE holds zero FDA-authorized SKUs. Turning Point Brands submitted Premarket Tobacco Product Applications (PMTAs) for its synthetic nicotine pouch lineup—including flagship flavors like Watermelon 12mg and Mint—but none have received marketing authorization. All FRE products remain on shelves under enforcement discretion while the FDA reviews pending applications. This places FRE in stark contrast to ZYN, which secured authorization for all 20 SKUs in January 2025.

FRE PMTA Portfolio: Current Status Breakdown

Turning Point Brands manufactures FRE as a tobacco-free, synthetic nicotine pouch line. The brand submitted PMTAs covering its core flavor and strength matrix, but the FDA has not issued authorizations for any variant as of mid-2026.

Key FRE SKUs and PMTA Status

Every FRE product currently sold carries the same regulatory designation: PMTA pending review, no FDA marketing authorization. This is a critical distinction consumers and retailers must understand when comparing FRE to brands like ZYN or on! PLUS, which have secured FDA authorization under the PMTA pathway.

The Synthetic Nicotine PMTA Pathway

FRE's regulatory journey differs from traditional tobacco-derived nicotine pouches. Prior to 2022, synthetic nicotine products existed in a gray zone—technically outside FDA tobacco jurisdiction. The Consolidated Appropriations Act of 2023 closed this loophole, bringing synthetic nicotine under the Federal Food, Drug, and Cosmetic Act's tobacco provisions.

Turning Point Brands faced a compressed timeline:

1. May 2022: Synthetic nicotine officially deemed a tobacco product
2. May 2023: PMTA submission deadline for synthetic nicotine manufacturers
3. 2023-2026: FDA review period (ongoing for FRE)

The FDA evaluates synthetic nicotine PMTAs using the same "appropriate for the protection of public health" standard applied to tobacco-derived products. Applications must demonstrate that marketing the product benefits public health—typically by showing adult smokers switch completely while minimizing youth uptake.

What Pending Status Means for FRE Consumers

Adults 21 and older can continue purchasing FRE pouches during the review period. The FDA allows compliant manufacturers to sell products with pending PMTAs under enforcement discretion—a policy designed to prevent market disruption while the agency works through a massive application backlog.

However, pending status carries uncertainty:

• No guarantee of approval: The FDA has issued Marketing Denial Orders (MDOs) to numerous flavored nicotine pouch applications, particularly for brands that failed to provide adequate youth prevention data
• Market instability: Retailers and distributors operate with the knowledge that any SKU could receive an MDO, forcing immediate removal from commerce
• Consumer perception: Products lacking authorization may face stigma compared to FDA-authorized competitors like ZYN (authorized January 2025) or on! PLUS (six SKUs authorized December 2025)

How FRE Compares to Authorized Brands

FRE shares pending status with major players like VELO and Rogue. The industry awaits clarity on whether flavored synthetic nicotine pouches will receive the same treatment as flavored tobacco-derived products, many of which have faced MDOs.

What's Next: Three Possible Outcomes

The FDA will resolve FRE's pending PMTAs through one of three actions:

1. Marketing Authorization

The FDA grants permission to sell specific SKUs. This requires demonstrating that adult smokers 21 and older benefit from switching to FRE while youth access remains minimal. ZYN's January 2025 authorizations provide a template: robust age verification, restricted marketing, and post-market surveillance commitments.

2. Marketing Denial Order (MDO)

The FDA prohibits sale of specific SKUs, typically citing insufficient evidence of public health benefit or concerns about youth appeal. Flavored products face heightened scrutiny. An MDO forces manufacturers to cease distribution within 30 days.

3. Continued Review

Applications remain in limbo. The FDA's tobacco product review process has no statutory deadline for PMTA decisions, though the agency faces mounting pressure from manufacturers, public health advocates, and Congress to resolve the backlog.

Industry Implications

FRE's pending status reflects broader challenges facing the nicotine pouch category. As of June 2026:

• Only 27 nicotine pouch SKUs hold FDA authorization (20 ZYN + 7 on! PLUS)
• Hundreds of pending PMTAs await decisions
• Market share concentration: Authorized products gain retailer preference and consumer trust

Turning Point Brands continues marketing FRE under enforcement discretion, but the competitive landscape favors authorized alternatives. Retailers 21-and-older increasingly prioritize FDA-cleared inventory to mitigate regulatory risk.

The FDA's approach to synthetic nicotine PMTAs will shape the industry's future. If the agency applies the same standards used for tobacco-derived flavored pouches, FRE's fruit and dessert flavors face an uphill battle. Conversely, authorizations for FRE Mint or Wintergreen could signal a pathway for synthetic nicotine products that mirror traditional tobacco flavors.

Resources for Consumers

Adults 21 and older seeking FDA guidance on nicotine pouches should consult:

• FDA Tobacco Products Overview
• CDC Tobacco Data and Statistics
• Smokefree.gov Cessation Resources

For real-time PMTA updates, monitor the FDA's tobacco product applications page, though the agency does not publish comprehensive pending application lists.

The Bottom Line

FRE's PMTA status as of June 2026 is unambiguous: no FDA-authorized SKUs, all pending review. Consumers 21 and older can purchase FRE pouches, but regulatory uncertainty persists. For those prioritizing FDA-cleared products, ZYN and on! PLUS represent the only authorized nicotine pouch options on the U.S. market. The coming months will determine whether FRE joins that exclusive group or faces the same Marketing Denial Orders issued to dozens of competing brands.